Table 1.
Descriptive characteristics of the cohort.
| Patients receiving vernakalant solely (n = 167) | Patients receiving vernakalant and ecv (n = 63) | P-value | |
|---|---|---|---|
| Demographics | |||
| Age, median (IQR) | 61 (48–68) | 59 (52–70) | 0,698 |
| Female, n (%) | 58 (34,7) | 19 (30,2) | 0,512 |
| Body mass index, median (IQR) | 27 (24–30) | 27 (24–30) | 0,236 |
| Chronic health conditions | |||
| Hypertension, n (%) | 105 (62,9) | 42 (66,7) | 0,593 |
| Diabetes, n (%) | 10 (6,0) | 10 (15,9) | 0,065 |
| COPD, n (%) | 8 (4,8) | 1 (1,6) | 0,264 |
| Serum creatinine >200 mmol/l, n (%) | 10 (6,0) | 3 (4,8) | 0,720 |
| Coronary artery disease, n (%) | 11 (6,6) | 6 (9,5) | 0,448 |
| Preexisting risk factors | |||
| Valvular heart disease, n (%) | 18 (10,8) | 11 (17,5) | 0,173 |
| Previous atrial fibrillation ablation therapy, n (%) | 26 (15,6) | 18 (28,6) | 0,384 |
| Concomitant anti-arrhythmic treatment | |||
| Beta-blocker, n (%) | 86 (51,5) | 22 (34,9) | 0,078 |
| Calcium channel blocker, n (%) | 14 (8,4) | 6 (9,5) | 0,784 |
| Amiodarone, n (%) | 11 (6,6) | 7 (11,1) | 0,255 |
| Dronedarone, n (%) | 8 (4,8) | 3 (4,8) | 0,993 |
Unless otherwise indicated, data are numbers (percentages); ecv = electrical cardioversion; IQR = interquartile range; n = number; COPD = chronic obstructive pulmonary disease.